thousands of cancer sufferers will lose out on ` last chance ' drugs after the nhs withdrew approval for their use .
the cancer drugs fund for england has cut 19 life-extending treatments it claims are too expensive after a review in january .
they include jevtana , used in prostate cancer , along with zaltrap , avastin and erbitux for bowel cancer .